Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796584 · ClinicalTrials.gov registry record
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
A clinical trial, sponsored by Providence Health & Services.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04796584: Clinical Trial study, sponsored by Providence Health & Services.
NCT04796584 is a clinical trial that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04796584 was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with MS when compared to healthy controls not receiving immunomodulating medications. We hypothesize that the use of immunomodulators in MS patients may eliminate or reduce the level of protective immune response, and/or shorten the duration of the protective response.
Primary Outcome
Serum Sample
Interventions
- OTHER Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2022-10-25 |
Why NCT04796584 stopped before completion
NCT04796584 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus is the first listed.
NCT04796584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04796584 about?
NCT04796584 is a clinical study titled "Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication". The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with MS when compared to healthy controls not receiving immunomodulating medi...
What is the current status of trial NCT04796584?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2022-07-11. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT04796584?
The interventions under investigation include: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus (OTHER).
Who is sponsoring clinical trial NCT04796584?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI